Frontlight ResearchEarly access
CompletedNo phase
Semi-automatic Segmentation Method for Determining 177Lu-DOTATATE Tumor Dosimetry
Key facts
- Who runs it
- Central Hospital, Nancy, France
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 25 people enrolled
- Started
- 1 Nov 2024
- Ended
- 28 Feb 2025
- Type of study
- Observational
- Treatments tested
- scintigraphy of 177Lu-DOTATATE
- Record updated
- 4 March 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Patients treated with 177Lu-DOTATATE for meningioma at Nancy University Hospital
- Patients with neuroendocrine tumors in the EVADOV study who underwent scintigraphy on D1, D4 and D7 (± 1 day)
Who cannot take part
- Patients who refused to have their data used retrospectively
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study was to compare a semi-automatic segmentation method with manual reference segmentation to determine an overall tumor volume on post-therapy scintigraphy at D1 in patients treated with 177Lu-DOTATATE for meningioma or neuroendocrine tumor for dosimetric calculation.
The group in the trial
- Patients treated with 177Lu-DOTATATE
Patients treated with 177Lu-DOTATATE for a meningioma at the Nancy University Hospital and for a neuroencrine tumor in the EVADOVE study NCT04467567 (who underwent scintigraphy on D1, D4 and D7 (± 1 day)
Treatment: scintigraphy of 177Lu-DOTATATE
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 4 March 2025